Gradients
Gradients

A mechanistic science of human flourishing

Abolishing drug tolerance with next-generation therapeutics

The Thesis

AI is radically accelerating all parts of the drug development pipeline, from discovery to experimental validation. What used to take a decade and a billion dollars is becoming faster and cheaper, and soon enough by orders of magnitude. We are on a mission to leverage breakthroughs in AI for developing therapeutics for pain, well-being, and other indications, with no tolerance or withdrawal, and vastly improved side-effect profiles.

Team

Leadership

Curran Jansens

Curran Jansens

Co-Founder & CEO

Max Novendstern

Max Novendstern

Co-Founder & Chairman

David Pearce

David Pearce

Bioethics Director

Michael Johnson

Michael Johnson

Advisor

Kristian Rönn

Kristian Rönn

Advisor

Contact

Next-generation therapeutics won't discover themselves. Let's talk.